Clinical Trial Update: Open-Label Study of SPN-812 Administered With Psychostimulants in Children and Adolescents With ADHD [Phase 4]

View source ↗

Summary

Open-label Phase 4 study evaluating SPN-812 (viloxazine) in combination with psychostimulants for children and adolescents with Attention-Deficit/Hyperactivity …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Attention Deficit Hyperactivity Disorder

Drugs mentioned

• SPN-812 (viloxazine)

Snippet

Sponsor: Supernus Pharmaceuticals, Inc. | Conditions: Attention-Deficit/Hyperactivity Disorder (ADHD) | Phase 4 | Status: COMPLETED | Results posted: 2024-05-01